Business, energy, technology, markets and global industry news from Business News Today

mycosis fungoides

PharmaDeviceNews mycosis fungoides
Innate Pharma’s lacutamab partnership with Sobi could unlock the TELLOMAK-3 Phase 3 trial and a potential accelerated approval pathway in T-cell lymphoma, with the licensing agreement carrying up to $580 million in potential value. Representative image.
Pharma & Biotech

What Sobi’s lacutamab licensing deal means for Innate Pharma and TELLOMAK-3

Innate Pharma’s Sobi deal brings $75m upfront and could unlock TELLOMAK-3, accelerated approval and global commercialization of lacutamab.

Read More